Biofrontera (BFRI) Competitors $0.89 +0.03 (+4.06%) Closing price 04:00 PM EasternExtended Trading$0.88 -0.01 (-0.58%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BFRI vs. PLUR, MRSN, XLO, KLTO, RNXT, BTAI, ESLA, EGRX, SCYX, and CLSDShould you be buying Biofrontera stock or one of its competitors? The main competitors of Biofrontera include Pluri (PLUR), Mersana Therapeutics (MRSN), Xilio Therapeutics (XLO), Klotho Neurosciences (KLTO), RenovoRx (RNXT), BioXcel Therapeutics (BTAI), Estrella Immunopharma (ESLA), Eagle Pharmaceuticals (EGRX), SCYNEXIS (SCYX), and Clearside Biomedical (CLSD). These companies are all part of the "pharmaceutical products" industry. Biofrontera vs. Its Competitors Pluri Mersana Therapeutics Xilio Therapeutics Klotho Neurosciences RenovoRx BioXcel Therapeutics Estrella Immunopharma Eagle Pharmaceuticals SCYNEXIS Clearside Biomedical Biofrontera (NASDAQ:BFRI) and Pluri (NASDAQ:PLUR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings. Do analysts prefer BFRI or PLUR? Biofrontera presently has a consensus price target of $2.75, suggesting a potential upside of 210.35%. Pluri has a consensus price target of $12.00, suggesting a potential upside of 127.70%. Given Biofrontera's higher possible upside, equities research analysts clearly believe Biofrontera is more favorable than Pluri.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Pluri 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals hold more shares of BFRI or PLUR? 10.1% of Biofrontera shares are owned by institutional investors. Comparatively, 16.6% of Pluri shares are owned by institutional investors. 4.8% of Biofrontera shares are owned by insiders. Comparatively, 25.9% of Pluri shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more risk & volatility, BFRI or PLUR? Biofrontera has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500. Comparatively, Pluri has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500. Is BFRI or PLUR more profitable? Biofrontera has a net margin of -42.34% compared to Pluri's net margin of -2,563.29%. Biofrontera's return on equity of -1,104.09% beat Pluri's return on equity.Company Net Margins Return on Equity Return on Assets Biofrontera-42.34% -1,104.09% -82.28% Pluri -2,563.29%-4,191.91%-85.40% Does the media prefer BFRI or PLUR? In the previous week, Biofrontera had 1 more articles in the media than Pluri. MarketBeat recorded 3 mentions for Biofrontera and 2 mentions for Pluri. Biofrontera's average media sentiment score of 1.29 beat Pluri's score of 0.63 indicating that Biofrontera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biofrontera 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pluri 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation & earnings, BFRI or PLUR? Biofrontera has higher revenue and earnings than Pluri. Pluri is trading at a lower price-to-earnings ratio than Biofrontera, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiofrontera$37.32M0.24-$17.76M-$2.26-0.39Pluri$330K125.68-$20.89M-$5.53-0.95 SummaryBiofrontera beats Pluri on 10 of the 14 factors compared between the two stocks. Get Biofrontera News Delivered to You Automatically Sign up to receive the latest news and ratings for BFRI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BFRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BFRI vs. The Competition Export to ExcelMetricBiofronteraMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.99M$3.08B$5.76B$9.75BDividend YieldN/A2.26%3.96%4.02%P/E Ratio-0.3920.9242.8226.39Price / Sales0.24355.43431.37159.28Price / CashN/A44.7137.7559.42Price / Book-1.938.0410.566.59Net Income-$17.76M-$53.98M$3.27B$265.83M7 Day Performance-8.05%-0.88%0.61%0.18%1 Month Performance-15.61%5.67%5.43%2.13%1 Year Performance-19.81%9.07%50.37%21.07% Biofrontera Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BFRIBiofrontera3.0811 of 5 stars$0.89+4.1%$2.75+210.3%-16.5%$8.99M$37.32M-0.3970Positive NewsGap UpPLURPluri2.208 of 5 stars$4.51-5.1%$12.00+166.1%-10.9%$37.39M$330K-0.82150MRSNMersana Therapeutics4.1269 of 5 stars$7.24-1.9%$56.60+681.8%-79.4%$36.83M$40.50M-0.50150XLOXilio Therapeutics3.1926 of 5 stars$0.68-3.6%$3.00+340.1%-14.8%$36.64M$6.34M-0.9070Positive NewsKLTOKlotho NeurosciencesN/A$0.78-0.2%N/AN/A$36.21MN/A-1.74N/APositive NewsRNXTRenovoRx3.0885 of 5 stars$0.92-2.0%$7.25+686.8%-5.2%$34.38M$40K-2.426BTAIBioXcel Therapeutics4.5171 of 5 stars$4.92-13.2%$39.75+707.9%-57.6%$34.34M$2.27M-0.3990News CoverageAnalyst DowngradeESLAEstrella Immunopharma3.1086 of 5 stars$0.92+0.1%$16.00+1,639.1%-18.6%$34.08MN/A-3.54N/APositive NewsGap UpEGRXEagle Pharmaceuticals1.6979 of 5 stars$2.60-18.8%N/A-40.6%$33.77M$257.55M0.00100News CoverageGap DownSCYXSCYNEXIS1.1468 of 5 stars$0.79-1.6%N/A-42.0%$33.65M$3.75M-1.9760CLSDClearside Biomedical2.66 of 5 stars$0.40-5.6%$4.20+944.8%-61.3%$33.44M$1.66M-1.0930Positive NewsGap Down Related Companies and Tools Related Companies PLUR Competitors MRSN Competitors XLO Competitors KLTO Competitors RNXT Competitors BTAI Competitors ESLA Competitors EGRX Competitors SCYX Competitors CLSD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BFRI) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biofrontera Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biofrontera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access